Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Art & Psychiatry
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Conference Oration
Conference Summary
Continuing Medical Education
Cosmetic Dermatology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
Editor Speaks
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Miscellaneous Letter
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News & Views
Observation Letter
Observation Letters
Original Article
Original Contributions
Pattern of Skin Diseases
Pediatric Dermatology
Pediatric Rounds
Presedential Address
Presidential Address
Presidents Remarks
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Study Letter
Study Letters
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapy Letter
Therapy Letters
View Point
What’s new in Dermatology
View/Download PDF

Translate this page into:

Study Letter
89 (
); 135-138

Efficacy of platelet-rich plasma in Asians with androgenetic alopecia: A randomized controlled trial

Department of Dermatology, National Skin Centre, Singapore
Corresponding author: Senior Consultant, Sai Yee Chuah, Department of Dermatology, National Skin Centre, 1 Mandalay Rd, Singapore.
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Chuah SY, Tan CH, Wang ECE, Tan KT, Chan RKW, Zhao X, et al. Efficacy of platelet-rich plasma in Asians with androgenetic alopecia: A randomized controlled trial. Indian J Dermatol Venereol Leprol 2023;89:135-8.


Autologous platelet-rich plasma offers promise as a therapeutic option in androgenetic alopecia. Platelet-rich plasma is a concentrated suspension of platelets harvested from a patient’s venous blood. To date, there are only five prospective cohort studies and one randomized controlled trial in Asians.1 Thus, we conducted this 24-week, double-blind, placebo-controlled trial to investigate the impact of platelet-rich plasma in Asian patients of diverse ethnicities with androgenetic alopecia in Singapore. The study protocol was assessed and approved by the Ethics committee from the National Healthcare Group Institutional Review Board. The trial is registered under the Health Services Authority of Singapore and was granted approval for conduct under the Medicines (Clinical Trials) Regulations, 1978.

Platelet-rich plasma was prepared using the platelet-rich plasma RegenKit® (NeoAsia (S) Pte Ltd).2 Every participant received platelet-rich plasma injections, randomized to one half of the scalp, with the other half injected with normal saline (placebo treatment). A total of four treatment cycles every three weeks were carried out (Visits 1–4). They were reviewed at 12 and 24 weeks (Visit 5 and 6) for hair analysis with Folliscope® by LeedM Corp in Seoul, scalp photography of the vertex and occipital areas for comparison by three blinded dermatologists, and completion of a validated hair growth questionnaire.

Fifty patients (32 male, 18 female) of good general health completed the study. The clinical characteristics of our study participants are shown in Table 1. The results on hair density and hair diameter are shown in Table 2 and Figure 1.

Table 1:: Demographics and clinical characteristics of our study participants
N (%)
(n = 55)
(n = 34)
(n = 21)
Completion of all study visits 50 (90.9%) 32 (94.1%) 18 (85.7%)
Withdrawn 5 (9.1%) 2 (5.9%) 3 (14.3%)
 Withdrawn at week 12 3 (5.5%) 1 (2.9%) 2 (9.5%)
 Withdrawn at week 24 2 (3.6%) 1 (2.9%) 1 (4.8%)
 mean ± standard deviation (SD) 38.7 ± 10.5 36.5 ± 8.8 42.2 ± 12.2
 median (min, max) 38 (23, 70) 37 (23, 58) 39 (23, 70)
 Chinese 41 (74.6%) 23 (67.7%) 18 (85.7%)
 Malay 8 (14.5%) 6 (17.6%) 2 (9.5%)
 Indian 4 (7.3%) 3 (8.8%) 1 (4.8%)
 Filipino 2 (3.6%) 2 (5.9%) 0 (0.0%)
 Male 34 (61.8%) 34 (100.0%)
 Female 21 (38.2%) 21 (100.0%)
Patient Norwood-Hamilton level
 III 14 (41.2%) 14 (41.2%)
 IV 13 (38.2%) 13 (38.2%)
 V 5 (14.7%) 5 (14.7%)
 VI 2 (5.9%) 2 (5.9%)
Patient Ludwig level
 II 16 (29.6%) 16 (76.2%)
 III 5 (9.3%) 5 (23.8%)
Age of onset of AGA
 mean ± standard deviation (SD) 31.3 ± 10.7 30.2 ± 7.3 33.1 ± 14.6
 median (min, max) 29 (15, 65) 29 (15, 49) 26 (16, 65)
Duration of AGA
 mean ± SD 7.3 ± 5.5 6.2 ± 5.2 9.1 ± 5.7
 median (min, max) 5 (1, 20) 4.5 (1, 20) 8 (2, 20)

SD: Standard deviation, AGA: androgenetic alopecia

Table 2:: Summary of baseline hair density and diameter by treatment, and their changes from baseline at 12 weeks and 24 weeks for all participants and by gender
Placebo PRP treatment Placebo vs. PRP
Mean (95% CI) P* Mean (95% CI) P* P
All participants
Hair density (number of hair shafts/cm2)
 Baseline 128.8 (121.4, 136.2) 126.6 (119.1, 134.2) 0.48
 12 weeks - baseline 4.6 (-3.4, 12.6) 0.16 12.7 (5.8, 19.7) 0.001 0.10
 24 weeks - baseline 10.0 (1.0, 19.0) 0.02 14.1 (7.9, 20.3) <0.001 0.20
Hair diameter (μm)
 Baseline 66.9 (63.0, 70.8) 65.5 (62.0, 69.0) 0.41
 12 weeks - baseline –2.8 (–5.9, 0.2) 0.07 –1.1 (–3.6, 1.4) 0.62 0.35
 24 weeks - baseline –3.9 (–7.3, –0.5) 0.03 0.1 (-2.6, 2.9) 0.57 0.03
Hair density (number of hair shafts/cm2)
 Baseline 137.6 (128.7, 146.4) 134.9 (124.4, 145.3) 0.33
 12 weeks - baseline 4.8 (-3.8, 13.5) 0.25 16.7 (7.4, 26.1) 0.001 0.03
 24 weeks - baseline 11.8 (0.6, 23.0) 0.08 14.6 (5.6, 23.6) 0.002 0.27
Hair diameter (μm)
 Baseline 64.6 (59.6, 69.6) 63.2 (58.8, 67.7) 0.69
 12 weeks - baseline –4.0 (-8.1, 0.1) 0.05 –3.1 (–6.4, 0.3) 0.14 0.80
 24 weeks - baseline –5.9 (–10.4, –1.4) 0.01 –1.6 (–5.4, 2.2) 0.56 0.06
Hair density (number of hair shafts/cm2)
 Baseline 114.6 (103.8, 125.3) 113.2 (105.7, 120.7) 0.90
 12 weeks - baseline 4.3 (-12.0, 20.5) 0.44 5.8 (-3.4, 15.0) 0.21 0.89
 24 weeks - baseline 6.7 (-8.7, 22.1) 0.15 13.2 (6.5, 19.9) 0.002 0.57
Hair diameter (μm)
 Baseline 70.7 (64.4, 76.9) 69.1 (63.6, 74.6) 0.39
 12 weeks - baseline –0.8 (-5.4, 3.7) 0.63 2.3 (-1.2, 5.8) 0.18 0.25
 24 weeks - baseline –0.3 (–5.2, 4.7) 0.76 3.2 (-0.1, 6.5) 0.03 0.30

*P: P-value was obtained from the Wilcoxon signed-rank test for comparing the change in hair density or hair diameter from baseline to 12 weeks or 24 weeks vs. no change, PRP: Platelet-rich plasma

Figure 1:: Summary of change in hair density and hair diameter by treatment and gender at baseline, 12 weeks, and 24 weeks. Top panel shows the results for hair density. In male participants, there was significant increase on the PRP-treated side at both 12 weeks and 24 weeks, and significant increase on the saline-treated side (control) only at 24 weeks. In female participants, there was significant increase only on the PRP-treated side at 24 weeks. For all participants, there was significant increase at 12 and 24 weeks on PRP-treated side, and significant increase on the saline-treated side (control) only at 24 weeks. Bottom panel shows the results for hair diameter. In male participants, decrease in hair diameter was observed but only significant on the saline-treated side (control) at 24 weeks. In female participants, there was absolute increase in hair diameter on PRP-treated side at 12 and 24 weeks but did not reach statistical significance. For all participants, there was significant decrease in hair diameter on the saline-treated side (control) at 24 weeks. Points represent the means with whiskers indicating the 95% confidence intervals. Asterisks indicate significant difference compared with baseline within each treatment group based on bivariable analysis.

Overall, platelet-rich plasma injections resulted in an increase in hair density as early as in the first three months of treatment amongst male participants. Interestingly, there was no significant change in hair diameter with platelet-rich plasma but a progressive decrease in hair diameter with placebo treatment in our study. In androgenetic alopecia, hair miniaturization is characteristic and hence, hair diameter is expected to decrease over time. The maintenance of hair diameter on platelet-rich plasma-treated scalp suggests that platelet-rich plasma could provide the additional benefit of halting the reduction in hair shaft diameter. This effect was also reported in one Korean male patient with androgenetic alopecia.3 Moreover, multivariate analysis [Figure 2] revealed a trend towards progressive reduction in hair diameter in men with more advanced hair loss. This was also observed in a prospective cohort study done in China,4 suggesting that platelet-rich plasma should be initiated early for better efficacy.

Figure 2:: Regression coefficients (β) derived from multivariable linear mixed effect model for hair density (a, c) and hair diameter (b, d) by gender. Points are regression coefficients (β1) with whiskers indicating the 95% confidence intervals. If the 95% confidence interval does not cover zero, the corresponding regression coefficient is statistically significant

In our study, there was a trend of increased hair density in women treated with platelet-rich plasma [Figure 2] but this was not statistically significant when compared to placebo. The inability to reach significant change could be due to the lack of female participants. The sample size required for this study was calculated to assess the efficacy from baseline to 24 weeks within each treatment arm, particularly in men. The efficacy analysis for females and all participants were secondary and mainly exploratory. The data on the efficacy of platelet-rich plasma in women is still lacking, and future, larger controlled trials are required to determine if platelet-rich plasma is an effective modality for female pattern hair loss.

At 24 weeks, there was also a significant increase in hair density with saline injections. This was also seen in a recent study by Shapiro et al.5 We postulate that this effect may be explained by the release of growth factors and cytokines as part of the wound healing process secondary to scalp injections, similar to microneedling.

When comparing the scalp photographs, our clinicians found significant hair growth at both 12 and 24 weeks in all participants. Similarly, the self-administered survey revealed patients found the treatments effective at slowing down the hair loss process or aiding in hair growth. There was no significant difference in attitudes and satisfaction at 12 and 24 weeks, despite objective improvements at 12 weeks in hair density. This inconsistency may be attributed to a placebo effect, or the hair parameters measured may not be indicative of patient-perceived improvement. Platelet-rich plasma injections were also well-tolerated and, interestingly, yielded lower pain scores when compared with saline injections.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship


Conflict of interest

There are no conflicts of interest.


  1. , . Platelet-rich plasma and stem cells for hair growth: A review of the literature. Aesthet Surg J. 2020;40:NP177-88.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , , . Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period. J Cutan Aesthet Surg. 2014;7:213-9.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , . Letter: Platelet-rich plasma for treating male pattern baldness. Dermatol Surg. 2012;38:2042-44.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , , , , , et al. Efficacy of platelet-rich plasma for treating androgenetic alopecia of varying grades. Clin Drug Investig. 2019;39:865-72.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , , , . Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: A randomized controlled trial. J Am Acad Dermatol. 2020;83:1298-303.
    [CrossRef] [Google Scholar]

Fulltext Views

PDF downloads
View/Download PDF
Download Citations
Show Sections